MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$152,594,000
EPS
-$0.76
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-09-30
2025-06-30
Research and development
1,143,000
-
General and administrative
151,451,000
-
Formation and operating costs
-
374,857
Total operating expenses
152,594,000
-
Loss from operations
-152,594,000
-374,857
Income on trust account
-
18,080
Interest expense
-
28,345
Net loss and comprehensive loss
-152,594,000
-385,122
Basic EPS
-0.76
-
Diluted EPS
-0.76
-
Basic Average Shares
201,686,617
-
Diluted Average Shares
201,686,617
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss and
comprehensive loss
-$152,594,000
Loss from operations
-$152,594,000
Total operating
expenses
$152,594,000
General and
administrative
$151,451,000
Research and development
$1,143,000
Buy us a coffee
Semnur Pharmaceuticals, Inc. (DNQAF)
Semnur Pharmaceuticals, Inc. (DNQAF)